Compound 1 is a potent A ( 2A ) /A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4.1 nM ; A ( 1 ) K ( i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .
O O O O O B-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity I-ChemicalEntity O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature O B-OrganismTaxon O B-OrganismTaxon O O B-ChemicalEntity B-DiseaseOrPhenotypicFeature O B-OrganismTaxon O O B-ChemicalEntity B-DiseaseOrPhenotypicFeature O B-OrganismTaxon B-ChemicalEntity O B-ChemicalEntity O O O O O O O O B-ChemicalEntity I-OrganismTaxon O O O